Assessment of Platelet-derived GARP in Atherosclerotic Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Tissue sample and data collection.
- Who it may be relevant to
- Registry conditions: Atheroma; Carotid Artery, Atheromatosis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Belgium
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in tissue from patients with atherosclerosis, the carotid or femoral plaque representing a good source of residual material adequate for research purpose. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.
Interventions
- Other Tissue sample and data collection
Tissue sample and data collection
Primary outcome measures
- GARP Expression in Platelets [Time frame: Throughout the entire study, approximately during 3 years]
Secondary outcome measures (2)
- GARP Expression T Regulating Cells [Time frame: Throughout the entire study, approximately during 3 years]
- GARP Expression General [Time frame: Throughout the entire study, approximately during 3 years]
Eligibility criteria
Inclusion criteria
- Older than 18 years
- Able to give informed consent
- Undergoing carotid or femoral endarterectomy
Exclusion criteria
- Younger than 18 years
- Pregnant
- Dialysis
- Unable to give informed consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Belgium · 1 center
- Cliniques Universitaires Saint-Luc — Brussels
Identifiers
NCT: NCT07364058 · CAPGAD